Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Optinose Inc's Business Segments
Optinose Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 27
Regions Reported
-
Optinose Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - Q1 FY2025
- Product67.9%
Revenue by Product & Service Category - Q1 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 19 | 67.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Optinose Inc
Optinose Inc. is a pharmaceutical company that specializes in developing and commercializing innovative treatments for patients with various medical conditions. The company's primary focus is on developing unique drug delivery products to optimize the efficacy of medications.
Optinose has revolutionized drug delivery through its patented Exhalation Delivery Systems (EDS), which are designed to directly deliver medications deep into the nasal cavity. This innovative technology allows for controlled and precise delivery of drugs to the site of action, enhancing therapeutic outcomes and minimizing potential side effects.
The company's flagship product is XHANCE, an intranasal corticosteroid indicated for the treatment of nasal polyps in patients aged 18 years and older. XHANCE utilizes the Exhalation Delivery System to deliver a unique formulation of fluticasone propionate directly to the nasal passages, providing efficient and effective relief of nasal polyp symptoms.
Optinose's Exhalation Delivery Systems have various advantages over traditional drug delivery methods. By utilizing the natural breathing process, these devices can deliver consistent doses of medications across a wide range of patient populations. The mist produced by the device is also more likely to reach the targeted areas of the nasal cavity, ensuring better drug deposition and distribution.
In addition to XHANCE, Optinose has a robust pipeline of innovative products under development. These include potential treatments for various respiratory conditions, including chronic rhinosinusitis, nasal congestion, allergic rhinitis, and migraines. The company leverages its expertise in nasal drug delivery to develop targeted therapies that address unmet medical needs.
Optinose's commitment to research and development is reflected in its partnerships and collaborations with leading academic institutions, healthcare organizations, and pharmaceutical companies. These collaborations enable the company to access cutting-edge technologies, advance scientific knowledge, and accelerate the development of new treatment options.
Beyond its product portfolio, Optinose places strong emphasis on patient-centric care. The company works closely with healthcare professionals to educate patients about their conditions and treatment options. Optinose also offers comprehensive support programs to assist patients with access to therapy, financial assistance, and ongoing disease management.
In terms of global reach, Optinose operates in several regions, with its corporate headquarters in Yardley, Pennsylvania, United States. The company has established a strong presence in the United States market, and its products are also available in select European countries.
In summary, Optinose Inc. is a pharmaceutical company that specializes in developing and commercializing innovative drug delivery systems for various medical conditions. With its patented Exhalation Delivery Systems, the company aims to optimize medication delivery to the nasal cavity, improving therapeutic outcomes for patients. Through its flagship product XHANCE and a robust pipeline of potential treatments, Optinose is dedicated to advancing healthcare and providing effective solutions for patients worldwide.
Optinose has revolutionized drug delivery through its patented Exhalation Delivery Systems (EDS), which are designed to directly deliver medications deep into the nasal cavity. This innovative technology allows for controlled and precise delivery of drugs to the site of action, enhancing therapeutic outcomes and minimizing potential side effects.
The company's flagship product is XHANCE, an intranasal corticosteroid indicated for the treatment of nasal polyps in patients aged 18 years and older. XHANCE utilizes the Exhalation Delivery System to deliver a unique formulation of fluticasone propionate directly to the nasal passages, providing efficient and effective relief of nasal polyp symptoms.
Optinose's Exhalation Delivery Systems have various advantages over traditional drug delivery methods. By utilizing the natural breathing process, these devices can deliver consistent doses of medications across a wide range of patient populations. The mist produced by the device is also more likely to reach the targeted areas of the nasal cavity, ensuring better drug deposition and distribution.
In addition to XHANCE, Optinose has a robust pipeline of innovative products under development. These include potential treatments for various respiratory conditions, including chronic rhinosinusitis, nasal congestion, allergic rhinitis, and migraines. The company leverages its expertise in nasal drug delivery to develop targeted therapies that address unmet medical needs.
Optinose's commitment to research and development is reflected in its partnerships and collaborations with leading academic institutions, healthcare organizations, and pharmaceutical companies. These collaborations enable the company to access cutting-edge technologies, advance scientific knowledge, and accelerate the development of new treatment options.
Beyond its product portfolio, Optinose places strong emphasis on patient-centric care. The company works closely with healthcare professionals to educate patients about their conditions and treatment options. Optinose also offers comprehensive support programs to assist patients with access to therapy, financial assistance, and ongoing disease management.
In terms of global reach, Optinose operates in several regions, with its corporate headquarters in Yardley, Pennsylvania, United States. The company has established a strong presence in the United States market, and its products are also available in select European countries.
In summary, Optinose Inc. is a pharmaceutical company that specializes in developing and commercializing innovative drug delivery systems for various medical conditions. With its patented Exhalation Delivery Systems, the company aims to optimize medication delivery to the nasal cavity, improving therapeutic outcomes for patients. Through its flagship product XHANCE and a robust pipeline of potential treatments, Optinose is dedicated to advancing healthcare and providing effective solutions for patients worldwide.
As of late 2023, Optinose, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of specific diseases and disorders, particularly those related to the upper respiratory tract. Below is an extensive overview of their market segments, products, and services.
Market Segments
1. Pharmaceutical
- Prescriptive Medications: Optinose primarily operates in the pharmaceutical sector, offering prescription medications designed specifically for patients suffering from conditions affecting the nasal and sinus cavities.
2. Healthcare
- Provider Services: Optinose engages with healthcare providers, empowering them with tools and information necessary for effective patient management and treatment planning.
3. Patient Care
- Patient-Centered Solutions: The company places a strong emphasis on ensuring that patients have access to the medications they need, and it works on developing educational materials and support tools to improve patient adherence to therapy.
Products
1. Xhance (fluticasone propionate)
- Indication: Approved for the treatment of nasal polyps in adults and the treatment of chronic rhinosinusitis.
- Formulation: Xhance employs a novel delivery system that utilizes a patented device and formulation to ensure effective medication distribution directly to the nasal mucosa.
- Mechanism of Action: As a corticosteroid, it functions by reducing inflammation in the nasal passages, thereby alleviating symptoms associated with chronic sinus issues.
2. Commercial Product Pipeline
- Future Products: Optinose continually seeks to expand its product portfolio, with several investigational products in different phases of development. These may include formulations for other respiratory conditions or variations of existing treatments with improved efficacy or delivery mechanisms.
3. Collaborative Products
- Partnerships and Collaborations: Optinose may engage in partnerships for developing combination therapies or providing technology for drug delivery systems intended for other pharmaceutical companies.
Services
1. Patient Support Programs
- Adherence Programs: Designed to assist patients in understanding their treatment plans and maintaining compliance with their prescribed therapies.
- Educational Tools: Resources aimed at educating patients about their conditions, treatment options, and medication usage.
2. Healthcare Provider Resources
- Training and Support: Provision of training materials for healthcare professionals regarding the proper prescription and administration of their products.
3. Market Access Services
- Reimbursement Support: Services that assist healthcare providers in navigating the reimbursement landscape for medications, ensuring that patients have access to their prescribed treatments without undue financial burden.
4. Clinical Trials and Research
- Investigation and Development: The company conducts clinical trials to support the efficacy and safety of its products, gathering robust data to inform future products and indications.
5. Regulatory Affairs
- Compliance Services: Optinose engages in ensuring that its operations and products comply with the regulations set forth by health authorities, thereby maintaining standards necessary for product approval and market access.
In summary, Optinose, Inc. positions itself as a leader in the biopharmaceutical space, focusing on innovative treatments for nasal and sinus-related conditions through a suite of products and complementary services aimed at improving patient outcomes and supporting healthcare providers. The company remains committed to expanding its offerings and enhancing access to crucial therapeutic solutions in the healthcare market.
Market Segments
1. Pharmaceutical
- Prescriptive Medications: Optinose primarily operates in the pharmaceutical sector, offering prescription medications designed specifically for patients suffering from conditions affecting the nasal and sinus cavities.
2. Healthcare
- Provider Services: Optinose engages with healthcare providers, empowering them with tools and information necessary for effective patient management and treatment planning.
3. Patient Care
- Patient-Centered Solutions: The company places a strong emphasis on ensuring that patients have access to the medications they need, and it works on developing educational materials and support tools to improve patient adherence to therapy.
Products
1. Xhance (fluticasone propionate)
- Indication: Approved for the treatment of nasal polyps in adults and the treatment of chronic rhinosinusitis.
- Formulation: Xhance employs a novel delivery system that utilizes a patented device and formulation to ensure effective medication distribution directly to the nasal mucosa.
- Mechanism of Action: As a corticosteroid, it functions by reducing inflammation in the nasal passages, thereby alleviating symptoms associated with chronic sinus issues.
2. Commercial Product Pipeline
- Future Products: Optinose continually seeks to expand its product portfolio, with several investigational products in different phases of development. These may include formulations for other respiratory conditions or variations of existing treatments with improved efficacy or delivery mechanisms.
3. Collaborative Products
- Partnerships and Collaborations: Optinose may engage in partnerships for developing combination therapies or providing technology for drug delivery systems intended for other pharmaceutical companies.
Services
1. Patient Support Programs
- Adherence Programs: Designed to assist patients in understanding their treatment plans and maintaining compliance with their prescribed therapies.
- Educational Tools: Resources aimed at educating patients about their conditions, treatment options, and medication usage.
2. Healthcare Provider Resources
- Training and Support: Provision of training materials for healthcare professionals regarding the proper prescription and administration of their products.
3. Market Access Services
- Reimbursement Support: Services that assist healthcare providers in navigating the reimbursement landscape for medications, ensuring that patients have access to their prescribed treatments without undue financial burden.
4. Clinical Trials and Research
- Investigation and Development: The company conducts clinical trials to support the efficacy and safety of its products, gathering robust data to inform future products and indications.
5. Regulatory Affairs
- Compliance Services: Optinose engages in ensuring that its operations and products comply with the regulations set forth by health authorities, thereby maintaining standards necessary for product approval and market access.
In summary, Optinose, Inc. positions itself as a leader in the biopharmaceutical space, focusing on innovative treatments for nasal and sinus-related conditions through a suite of products and complementary services aimed at improving patient outcomes and supporting healthcare providers. The company remains committed to expanding its offerings and enhancing access to crucial therapeutic solutions in the healthcare market.